1h Free Analyst Time
The biosimilars market is forecasted to grow by USD 54.35 billion during 2023-2028, accelerating at a CAGR of 23.63% during the forecast period. The report on the biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by price advantage of biosimilars over biologics, patent expiry of major biologics, and government initiatives to increase use of biosimilar medicines.
The biosimilars market is segmented as below:
By Product Type
- Monoclonal antibodies
- Insulin
- Human growth hormone
- Others
By Application
- Oncology and hematology
- Endocrinology
- Immunology
- Nephrology
By Geographical Landscape
- Europe
- North America
- Asia
- Rest of World (ROW)
The report on the biosimilars market covers the following areas:
- Biosimilars market sizing
- Biosimilars market forecast
- Biosimilars market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global biosimilars market: AbbVie Inc., Amgen Inc., Biocon Ltd., Biogen Inc., Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gedeon Richter Plc, Halozyme Therapeutics Inc., Intas Pharmaceuticals Ltd., Mabion S.A., Novartis AG, Pfizer Inc., Samsung Biologics Co. Ltd., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is patients and physician's willingness to switch to biosimilars."
According to the report, one of the major drivers for this market is the price advantage of biosimilars over biologics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Biocon Ltd.
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Celltrion Healthcare Co. Ltd.
- Dr Reddys Laboratories Ltd.
- F. Hoffmann La Roche Ltd.
- Fresenius SE and Co. KGaA
- Gedeon Richter Plc
- Halozyme Therapeutics Inc.
- Intas Pharmaceuticals Ltd.
- Mabion S.A.
- Novartis AG
- Pfizer Inc.
- Samsung Biologics Co. Ltd.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
